Clinical Study Report (CSR)

A Clinical Study Report (CSR) is the comprehensive document that summarizes a clinical trial’s design, conduct, and results in a single, standardized package, prepared according to ICH guideline E3, Structure and Content of Clinical Study Reports. It is the primary artifact a sponsor submits to regulators as evidence that a trial supports the safety and efficacy claims of a marketing application, and — increasingly — an artifact regulators make public in some form after a decision is reached.

What ICH E3 Requires

ICH E3 lays out a standard outline so that a single core CSR can, in principle, be acceptable to regulatory authorities across the ICH regions rather than requiring a differently structured report per jurisdiction. The guideline is explicitly a framework, not a rigid template — sponsors are expected to adapt section content to what actually communicates the trial clearly — but the core skeleton is consistent across CSRs industry-wide:

• Title page — trial name, sponsor, investigational product, protocol number, and report date.
• Synopsis — a standalone summary, conventionally limited to about three pages, covering objectives, design, key efficacy and safety results with actual numbers, and conclusions; this is frequently the only section a reviewer reads in full on a first pass.
• Ethics — IRB/IEC approvals, informed consent procedures, and any ethical considerations specific to the trial.
• Investigators and study administrative structure.
• Introduction and study objectives — therapeutic rationale and the primary/secondary objectives being tested.
• Investigational plan — overall design, discussion of design choices, study population, treatments, and efficacy/safety variables.
• Study patients — disposition, protocol deviations, and demographic/baseline characteristics.
• Efficacy evaluation — analysis populations, statistical methods, and results for each endpoint.
• Safety evaluation — exposure, adverse events, deaths, laboratory findings, and other safety data.
• Discussion and overall conclusions.
• Tables, figures, and graphs, followed by an extensive set of appendices — typically including the protocol and amendments, a sample case report form, the list of IRBs/IECs and investigators, signatures, any related publications, and (where required) patient data listings.

Because a CSR narrates and analyzes a trial’s clinical trial data after that data has been finalized, it is compiled only once database lock has occurred — see CASRAI’s Clinical Trial Data term for how source data, CRF entries, and locked datasets relate. The CSR’s protocol appendix and investigator list draw on records that also live in the trial’s Trial Master File (TMF), but the CSR is a distinct artifact from the TMF: the TMF is the evidentiary document set proving the trial was conducted according to ICH E6(R2) Good Clinical Practice, while the CSR is the single narrative report analyzing what the trial found.

Regulatory Role: Marketing Applications

The CSR is a core component of the clinical section of a marketing application — an NDA or BLA submitted to FDA, a Marketing Authorisation Application (MAA) submitted to the EMA, or the equivalent submission to Health Canada and other ICH-region regulators. Where a sponsor’s marketing application is refused in its submitted form, the CSR and its underlying data are frequently central to the deficiencies a regulator cites; see CASRAI’s Complete Response Letter (CRL) term for how FDA’s non-approval notice relates to the evidence a CSR presents.

Public Disclosure: EMA Policy 0070 and Health Canada’s PRCI

For decades, CSRs were treated by sponsors and regulators as confidential commercial information, visible only to the regulator that received them. That has changed materially over the past decade, driven by two overlapping transparency initiatives:

• EMA Policy 0070 (“Publication of clinical data for medicinal products for human use”) commits the European Medicines Agency to proactively publish clinical reports — including CSRs — submitted as part of centralized marketing authorization applications, once a regulatory decision has been reached. Sponsors prepare a redacted, publicly releasable version of each CSR, with commercially confidential information and personal data removed, following EMA’s redaction guidance. The policy’s scope and cadence have shifted over time (implementation began in the mid-2010s, was paused, and was relaunched in September 2023 covering new active-substance applications, including negative opinions, withdrawn applications, and major Type II variations); sponsors preparing a submission should check EMA’s current Policy 0070 guidance for the scope in force at the time of filing, rather than assume a fixed rule.
• Health Canada’s Public Release of Clinical Information (PRCI) guidance similarly requires sponsors to make clinical information — including CSRs — from drug and medical device submissions publicly available, subject to redaction of confidential business information and personal information, to support independent analysis of the evidence behind a regulatory decision. Health Canada and the EMA have also established a work-share arrangement for jointly reviewed applications, intended to reduce duplicated redaction and disclosure effort for sponsors filing with both agencies.

The practical effect for sponsors is that a CSR is no longer written for a single regulatory audience: a document originally structured to ICH E3 for internal regulatory review may also need a companion redacted version suitable for public release, prepared to each regulator’s specific redaction and formatting rules.

Worked Example

A sponsor completes a pivotal Phase III trial and locks the database. Biostatistics finalizes the analysis, and medical writing compiles a full ICH E3-structured CSR — synopsis, all 16 numbered body sections, and appendices including the protocol, sample CRF, and investigator list — as the core clinical evidence package for a marketing application filed simultaneously with FDA, the EMA, and Health Canada. Because the EMA and Health Canada applications fall under Policy 0070 and PRCI respectively, the sponsor also prepares redacted versions of the same CSR for eventual public release once each agency reaches its decision.

Counter-Example

A results summary posted to a public trial registry, or a manuscript reporting the trial’s findings in a peer-reviewed journal, is not a CSR. Both may describe the same trial and even share underlying data, but neither follows the ICH E3 structure, neither is submitted to a regulator as the evidentiary basis for a marketing decision, and neither carries the full statistical and safety detail — including individual adverse event listings and appendices — that a CSR is structured to contain.

Related Terms

See also CASRAI’s Trial Master File (TMF), Clinical Trial Data, and Complete Response Letter (CRL) terms for how the CSR relates to a trial’s document-compliance record, its underlying data, and FDA’s non-approval mechanism.